Leonardi C
Efalizumab: results of a 3-year continuous dosing study for
the long-term control of psoriasis
British Journal of Dermatology 2008 158, pp1107–1116 (PDF 485KB)

Ulmer A
Severe exacerbation of chronic plaque psoriasis following initially effective therapy with efalizumab: clinical characterization and therapeutic management
Br J Dermatol. 2008 Apr;158(4):867-9. Epub 2008 Feb 16

Varma R
Safety and Efficacy of Subcutaneously Administered Efalizumab in Adults with Moderate-to-Severe Hand and Foot Psoriasis: An Open-Label Study
Am J Clin Dermatol. 2008;9(2):105-9

Gisondi P
Combination of efalizumab and acitretin in chronic plaque psoriasis
Journal of the European Academy of Dermatology and Venereology, Volume 22, Issue 2, Page 247-248, Feb 2008

Menter A
Transitioning patients from efalizumab to alternative psoriasis therapies: findings from an open-label, multicenter, Phase IIIb study
Int J Dermatol. 2007 Jun;46(6):637-48

Dubertret L
Clinical experience acquired with the efalizumab (Raptiva) (CLEAR) trial in patients with moderate-to-severe plaque psoriasis: results from a phase III international randomized, placebo-controlled trial
Br J Dermatol. 2006 Jul;155(1):170-81

Papp KA
Safety of efalizumab in adults with chronic moderate to severe plaque psoriasis: a phase IIIb, randomized, controlled trial
Int J Dermatol. 2006 May;45(5):605-14

Gordon KB
Efalizumab for patients with moderate to severe plaque psoriasis: a randomized controlled trial
JAMA. 2003 Dec 17;290(23):3073-80